Deal Experts for Korean Biopharma


The Biopharma industry in South Korea has grown significantly in the past decade. Having traditionally focused on generics and manufacturing, the industry has now transformed into an engine of innovation driven by the country’s cutting-edge science and technology.

Despite this achievement, however, many South Korean biopharma companies have struggled to reap the rewards of their hard work due to the challenges in accessing the global market. A popular solution to overcoming those challenges has been partnering & alliances with global biopharma.

How can we help you?

Over the past few years, PharmaVentures has successfully carried out over 40 BD&L projects with Korean clients. Leveraging over 30 years of experience in the global biopharma deal making scene, PharmaVentures has helped Korean companies to meet their strategic objectives by providing the following services:

In/out-licensing support for assets across different development stages
Valuation of assets/companies
Market research to support corporate strategy (e.g., asset development, indication prioritisation)
Pricing and Market Access

We also have 4 bilingual Korean speakers in our execution team with strong scientific/technical background, enabling PharmaVentures to provide differentiated services to Korean clients interested in exploring new business opportunities across the globe.

Dedicated Advisors

JungHyun Eom
Phone: +82 10 4388 9400

Jessie (Sangmin) You

Adrian Dawkes​
Managing Director
Phone: +44 (0) 7931 428487 

12-14 July 2023

Bioplus Interphex Korea

JungHyun Eom is available for 1-1 meetings.

Previous Events

PharmaVentures is in partnership with several Korean government institutions to provide educational and thought leadership activities and is working towards globalising the Korean biopharma industry.

We have delivered numerous education series through various platforms to cover some of the basic concepts of deal making and share the best practice in negotiation and deal closure. Please find below different seminars and events that we have participated in the past:

10-12 May 2023

BIO Korea 2023

JungHyun Eom was available for 1-1 meetings.

11-13 May 2022

BIO Korea 2022

Dr Adrian Dawkes presented a talk on Device and Diagnostics Licensing. JungHyun Eom was available for 1-1 meetings.

7-8 October 2021

Seoul International Biomedical Conference

Dr Luke Lee, Associate, will be attending this event in person and will be available for 1-1 meetings.

11-13 October 2021

CPhI Korea

Dr Luke Lee, Associate, will be attending this event in person and will be available for 1-1 meetings.

21 October 2021

Seongnam International Medical Tourism Convention 2021

Dr Adrian Dawkes, Managing Director, will be presenting a session on the impact of COVID-19 on deal trends.

Our Case Studies

PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD

PharmaVentures is pleased to announce that it acted as exclusive advisor for Wellmarker Bio Co., Ltd (WMBIO) on its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.

PharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics

PharmaVentures is pleased to announce that it acted as exclusive advisor for IntoCell on its agreement with ADC Therapeutics (NYSE: ADCT).

PharmaVentures advises IntoCell on its Research Collaboration with Ab Studio

PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio.

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

PharmaVentures acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4.

Valuation advisor to Yuhan Corporation on its licensing of Lazertinib for NSCLC to Janssen

At the time of engaging PharmaVentures, Yuhan had been in dialogue with a number of potential licensees. In order to strengthen the Lazertinib story, Yuhan requested PharmaVentures to conduct a comprehensive valuation of the asset.

Watch On-Demand


On the 24th June, Dr Adrian Dawkes, Managing Director, and Dr Luke Lee, Associate, took part in a valuation series at SEOUL BIOHUB to share insight into key valuation concepts and modelling approaches to support transactions with case study examples and live Q&A.

The valuation series includes:

• Seminar 1: Asset Valuation 101
• Seminar 2: Advanced Valuation Concepts
• Seminar 3: Real-World Application and Case Studies
• Q&A session

Watch On Demand


On the 12th June 2020, Dr Adrian Dawkes, Managing Director, and Summer Park, Senior Business Development Director, took part in a number of live sessions at SEOUL BIOHUB 2020.